Clinical Trial Update: Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating atrasentan to reduce residual albuminuria in people with diabetes and nephropathy has completed. The results may inform potential kidne…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Diabetic Nephropathy

Drugs mentioned

• Atrasentan (atrasentan)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Kidney Disease, Diabetic Nephropathy | Phase 2 | Status: COMPLETED